---
title: "HISOAR: The market holds an overall optimistic attitude towards the price recovery of Peinan products"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248101215.md"
description: "HISOAR stated in its latest investor relations activity that the price of Peinan products has shown signs of recovery in the second quarter of this year after a continuous decline, and the market is optimistic about the restoration of its prices. The company maintains communication with global customers and suppliers, paying attention to whether the price can continue to recover. HISOAR has laid out in multiple fields such as anti-infection and blood sugar reduction, with related products at different stages of research and development, which is expected to broaden its development space in the future"
datetime: "2025-07-11T06:10:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248101215.md)
  - [en](https://longbridge.com/en/news/248101215.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248101215.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/248101215.md) | [繁體中文](https://longbridge.com/zh-HK/news/248101215.md)


# HISOAR: The market holds an overall optimistic attitude towards the price recovery of Peinan products

HISOAR stated in the latest disclosed investor relations activity record that in terms of raw materials, the price of penicillin products has been continuously declining and hitting new lows in recent years, but there was some recovery in the second quarter of this year, showing a trend of stabilization and rebound; the company maintains communication with global customers and suppliers and has learned that the market holds an overall optimistic attitude towards the price recovery of penicillin products. Whether the price of penicillin products can continue to recover remains to be further observed. The company has laid out multiple fields in raw materials, including anti-infection, hypoglycemic, dermatology, ophthalmology medications, and psychiatric drugs, with related products currently in various stages of research and development such as small-scale trials, pilot tests, and validation. Continuous approvals in the future will expand the company's development space

### Related Stocks

- [HISOAR (002099.CN)](https://longbridge.com/en/quote/002099.CN.md)

## Related News & Research

- [Tennis-Djokovic reaches Indian Wells last 16 as Pegula fights back to progress](https://longbridge.com/en/news/278446416.md)
- [Know a rising star in pharma marketing? Nominate them here](https://longbridge.com/en/news/278461777.md)
- [Asia Distillates-Diesel cash premiums at record high; jet fuel window deals brisk](https://longbridge.com/en/news/278386243.md)
- [Two men charged with terrorism after homemade bomb thrown at anti-Islam protesters in New York](https://longbridge.com/en/news/278436990.md)
- [17:02 ETEXPLORA JOURNEYS CELEBRATES TRIPLE MARITIME MILESTONE AS LUXURY FLEET EXPANSION ACCELERATES](https://longbridge.com/en/news/278447492.md)